Stay updated on Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial page.

Latest updates to the Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial page
- CheckyesterdayChange DetectedThe expected modernization of the ClinicalTrials.gov data ingest has been updated to July 2025, with a revision change from v2.16.3 to v2.16.4.SummaryDifference2%
- Check8 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check15 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check22 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1.0%
- Check51 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check65 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed descriptions of soft tissue sarcomas and the study's methodology, while adding new collaborators and a revision number. The study now emphasizes the involvement of Merck Sharp & Dohme LLC and specifies the study's location.SummaryDifference64%
Stay in the know with updates to Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial page.